ARID1A and TERT promoter mutations in dedifferentiated meningioma

Cancer Genetics

Volumn 208, Issue 6, 2015, Pages 345-350

  Abedalthagafi, Malak S ^a   Bi, Wenya Linda ^a   Merrill, Parker H ^a   Gibson, William J ^b   Rose, Matthew F ^a   Du, Ziming ^a   Francis, Joshua M ^b,c   Du, Rose ^a   Dunn, Ian F ^a   Ligon, Azra H ^a   Beroukhim, Rameen ^b,c   Santagata, Sandro ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c BROAD INSTITUTE OF MIT AND HARVARD   (United States)

Author keywords

Anaplastic; Chromatin remodeling; Intratumoral heterogeneity; Meningioma; SWI SNF complex

Indexed keywords

GENOMIC DNA; MESSENGER RNA; PROTEIN ARID1A; TELOMERASE REVERSE TRANSCRIPTASE; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG; ARID1A PROTEIN, HUMAN; NUCLEAR PROTEIN; TELOMERASE; TERT PROTEIN, HUMAN;

ADULT; ANEUPLOIDY; ARID1A GENE; ARTICLE; CANCER GRADING; CANCER GROWTH; CANCER MORPHOLOGY; CASE REPORT; CELL DEDIFFERENTIATION; CLINICAL FEATURE; COMPARATIVE GENOMIC HYBRIDIZATION; CONTRAST ENHANCEMENT; COPY NUMBER VARIATION; CRANIOTOMY; DEDIFFERENTIATED MENINGIOMA; FEMALE; FRAMESHIFT MUTATION; GAIT DISORDER; GENE MUTATION; GENETIC HETEROGENEITY; GENETIC PROCEDURES; HEADACHE; HETEROZYGOSITY LOSS; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MENINGIOMA; MIDDLE AGED; MOLECULAR PATHOLOGY; OBSTRUCTIVE HYDROCEPHALUS; PHENOTYPE; POSTOPERATIVE CARE; PRIORITY JOURNAL; PROMOTER REGION; SINGLE NUCLEOTIDE POLYMORPHISM; TERT GENE; WHOLE EXOME SEQUENCING; DISEASE COURSE; GENETICS; MUTATION; PATHOLOGY; TUMOR RECURRENCE;

DISEASE PROGRESSION; FEMALE; HUMANS; MENINGEAL NEOPLASMS; MENINGIOMA; MIDDLE AGED; MUTATION; NEOPLASM RECURRENCE, LOCAL; NUCLEAR PROTEINS; PROMOTER REGIONS, GENETIC; TELOMERASE; TRANSCRIPTION FACTORS;

EID: 84937974103     PISSN: 22107762     EISSN: 22107770     Source Type: Journal    
DOI: 10.1016/j.cancergen.2015.03.005     Document Type: Article

References (31)

1. Wiemels J., Wrensch M., Claus E.B. Epidemiology and etiology of meningioma. JNeurooncol 2010, 99:307-314.
2. Goutagny S., Nault J.C., Mallet M., et al. High incidence of activating TERT promoter mutations in meningiomas undergoing malignant progression. Brain Pathol 2014, 24:184-189.
3. Abedalthagafi M.S., Merrill P.H., Bi W.L., et al. Angiomatous meningiomas have a distinct genetic profile with multiple chromosomal polysomies including polysomy of chromosome 5. Oncotarget 2014, 5:10596-10606.
4. Smith M.J., O'Sullivan J., Bhaskar S.S., et al. Loss-of-function mutations in SMARCE1 cause an inherited disorder of multiple spinal meningiomas. Nat Genet 2013, 45:295-298.
5. Sahm F., Bissel J., Koelsche C., et al. AKT1E17K mutations cluster with meningothelial and transitional meningiomas and can be detected by SFRP1 immunohistochemistry. Acta Neuropathol 2013, 126:757-762.
6. Reuss D.E., Piro R.M., Jones D.T., et al. Secretory meningiomas are defined by combined KLF4 K409Q and TRAF7 mutations. Acta Neuropathol 2013, 125:351-358.
7. Clark V.E., Erson-Omay E.Z., Serin A., et al. Genomic analysis of non-NF2 meningiomas reveals mutations in TRAF7, KLF4, AKT1, and SMO. Science 2013, 339:1077-1080.
8. Brastianos P.K., Horowitz P.M., Santagata S., et al. Genomic sequencing of meningiomas identifies oncogenic SMO and AKT1 mutations. Nat Genet 2013, 45:285-289.
9. Aavikko M., Li S.P., Saarinen S., et al. Loss of SUFU function in familial multiple meningioma. Am J Hum Genet 2012, 91:520-526.
10. Du Z., Abedalthagafi M., Aizer A.A., et al. Increased expression of the immune modulatory molecule PD-L1 (CD274) in anaplastic meningioma. Oncotarget 2015, 6:4704-4716.
11. Yang H.W., Kim T.M., Song S.S., et al. Alternative splicing of CHEK2 and codeletion with NF2 promote chromosomal instability in meningioma. Neoplasia 2012, 14:20-28.
12. Kliese N., Gobrecht P., Pachow D., et al. miRNA-145 is downregulated in atypical and anaplastic meningiomas and negatively regulates motility and proliferation of meningioma cells. Oncogene 2013, 32:4712-4720.
13. Choy W., Kim W., Nagasawa D., et al. The molecular genetics and tumor pathogenesis of meningiomas and the future directions of meningioma treatments. Neurosurg Focus 2011, 30:E6.
14. Wang F., Flanagan J., Su N., et al. RNAscope: a novel in situ RNA analysis platform for formalin-fixed, paraffin-embedded tissues. JMol Diagn 2012, 14:22-29.
15. Brastianos P.K., Taylor-Weiner A., Manley P.E., et al. Exome sequencing identifies BRAF mutations in papillary craniopharyngiomas. Nat Genet 2014, 46:161-165.
16. DePristo M.A., Banks E., Poplin R., et al. Aframework for variation discovery and genotyping using next-generation DNA sequencing data. Nat Genet 2011, 43:491-498.
17. McKenna A., Hanna M., Banks E., et al. The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res 2010, 20:1297-1303.
18. Cibulskis K., Lawrence M.S., Carter S.L., et al. Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nat Biotechnol 2013, 31:213-219.
19. International HapMap 3 Consortium, Altshuler D.M., Gibbs R.A., et al. Integrating common and rare genetic variation in diverse human populations. Nature 2010, 467:52-58.
20. Browning B.L., Yu Z. Simultaneous genotype calling and haplotype phasing improves genotype accuracy and reduces false-positive associations for genome-wide association studies. Am J Hum Genet 2009, 85:847-861.
21. Carter S.L., Cibulskis K., Helman E., et al. Absolute quantification of somatic DNA alterations in human cancer. Nat Biotechnol 2012, 30:413-421.
22. Riemenschneider M.J., Perry A., Reifenberger G. Histological classification and molecular genetics of meningiomas. Lancet Neurol 2006, 5:1045-1054.
23. INK4c) in atypical and anaplastic meningiomas. Am J Pathol 2001, 159:661-669.
24. Goutagny S., Yang H.W., Zucman-Rossi J., et al. Genomic profiling reveals alternative genetic pathways of meningioma malignant progression dependent on the underlying NF2 status. Clin Cancer Res 2010, 16:4155-4164.
25. Simon M., Park T.W., Leuenroth S., et al. Telomerase activity and expression of the telomerase catalytic subunit, hTERT, in meningioma progression. JNeurosurg 2000, 92:832-840.
26. Wu J.N., Roberts C.W. ARID1A mutations in cancer: another epigenetic tumor suppressor?. Cancer Disc 2013, 3:35-43.
27. Guan B., Wang T.L., Shih Ie M. ARID1A, a factor that promotes formation of SWI/SNF-mediated chromatin remodeling, is a tumor suppressor in gynecologic cancers. Cancer Res 2011, 71:6718-6727.
28. Dykhuizen E.C., Hargreaves D.C., Miller E.L., et al. BAF complexes facilitate decatenation of DNA by topoisomerase II α. Nature 2013, 497:624-627.
29. Eroglu E., Burkard T.R., Jiang Y., et al. SWI/SNF complex prevents lineage reversion and induces temporal patterning in neural stem cells. Cell 2014, 156:1259-1273.
30. Kadoch C., Hargreaves D.C., Hodges C., et al. Proteomic and bioinformatic analysis of mammalian SWI/SNF complexes identifies extensive roles in human malignancy. Nat Genet 2014, 45:592-601.
31. Craig J.M., Vena N., Ramkissoon S., et al. DNA fragmentation simulation method (FSM) and fragment size matching improve aCGH performance of FFPE tissues. PLoS One 2012, 7:e38881.